MindChild Medical, Inc. To Present the MERIDIAN™ Non-Invasive Fetal Heart Rate Monitor at the 33rd Annual Meeting for the Society for Maternal Fetal Medicine (SMFM) to be Held February 13-15, 2013 in

NORTH ANDOVER, Mass. -- (BUSINESS WIRE) -- MindChild Medical, Inc. will present the MERIDIAN™ non-invasive fetal heart monitor at the 33rd Annual Meeting for the Society for Maternal Fetal Medicine (SMFM) to be Held February 13-15, 2013 at the Hilton Hotel, San Francisco, CA, booth 602.

Adam Wolfberg, M.D., Chief Medical Officer for MindChild stated, “The Society for Maternal Fetal Medicine is the premier meeting, bringing together clinicians and industry, focusing on the needs of the obstetric community. Now that we have received 510(k) pre-marketing notification clearance from FDA for MERIDIAN, we look forward to introducing MERIDIAN to the obstetric community.”

Previous Announcements

On November 5, 2012, MindChild Medical, Inc., and The University of Oxford announced a Sponsored Research Agreement for the Development of Innovative Signal Processing Software for Fetal and Maternal Monitor with the MERIDIAN™ Non-Invasive Fetal Heart Rate Monitor.

On September 25, 2012, MindChild announced clearance of a 510(k) Pre-Marketing Notification with the US Food and Drug Administration (FDA) for the MERIDIAN™ Non-Invasive Fetal Heart Rate Monitor.

On June 18, 2012, MindChild announced the appointment Thomas Garite, M.D. to the Clinical Advisory Board for the MERIDIAN Line of Non-Invasive Fetal Heart Rate Monitors.

On June 11, 2012, MindChild announced Results of National Fetal Monitoring Market Survey.

On February 22, 2012, MindChild reported formation of a Clinical Advisory Board for the MERIDIAN™ Line of Non-Invasive Fetal Heart Rate Monitors.

On February 6, 2012, MindChild reported filing of a 510(k) Pre-Marketing Notification Application with the US Food and Drug Administration for the MERIDIAN™ Line of Non-Invasive Fetal Heart Rate Monitors.

About the MERIDIAN Non-Invasive Fetal Heart Rate Monitor

MERIDIAN is a fetal monitor that non-invasively measures and displays fetal heart rate (FHR). MERIDIAN acquires and displays the FHR tracing from abdominal surface electrodes that detect the fetal ECG signal (fECG). MERIDIAN may also be used to measure and display fetal heart rate using direct ECG (DECG) with a Fetal Scalp Electrode (FSE). MERIDIAN is designed for women who are at term (> 36 completed weeks), in labor, with singleton pregnancies, using surface electrodes on the maternal abdomen. MERIDIAN is intended for use by healthcare professionals in a clinical setting.

About the Fetal Heart Monitoring Market

Over 85%¹ of the 4,000,000² live births occurring in the US during 2011 required fetal monitoring during labor and delivery. Current non-invasive Doppler, employing ultrasound to detect FHR is subject to loss of fetal heart rate due to maternal/fetal movement³. Fetal Scalp Electrodes (FSE) that connect directly to the fetus during the later stages of labor and delivery are associated with increased risk of maternal/fetal infection⁴. There are an estimated 28,000 fetal monitors spread over 3,400 hospitals in the US⁵, representing an investment of over $700,000,000⁶. MERIDIAN has been developed to provide uninterruptible fECG data while addressing the deficiencies in both Doppler and FSE via innovative non-invasive monitoring technology.

About the Society for Maternal-Fetal Medicine

The Society for Maternal-Fetal Medicine was established in 1977 and is the membership organization for obstetricians/gynecologists who have additional formal education and training in Maternal-Fetal medicine. There are currently about two thousand active members of the Society. The Society hosts an annual scientific meeting in which new ideas and research in the area of Maternal-Fetal Medicine are presented and there are additional frequent Continuing Medical Education courses provided by our members throughout the world. The Society is also an advocate for improving public policy and expanding research funding and opportunities in the area of maternal-fetal medicine.

About MindChild Medical, Inc.

MindChild Medical, Inc., is a privately funded medical device company founded in 2008. MindChild’s principal technology platform, the MERIDIAN non-invasive fetal electrocardiograph (fECG) monitor, is designed to report fetal heart rate data equivalent to the gold standard fetal scalp electrode in addition to novel ECG metrics intended to provide obstetricians a deeper understanding of fetal/maternal health and management.

MindChild was co-founded by Adam Wolfberg, MD, previously Assistant Professor, Tufts Medical Center (currently an associate at Boston Maternal-Fetal Medicine), Gari Clifford, PhD, previously Principal Research Scientist at Harvard-MIT Division of Health and Science Technology (currently on the faculty at the University of Oxford in the Department of Engineering Science), James Robertson, President and CEO, and Jay Ward, Executive Vice President, both of E-TROLZ, Inc. MindChild has exclusively licensed intellectual property from the Massachusetts Institute of Technology, Tufts Medical Center and E-TROLZ, Inc., a Massachusetts technology company that develops and commercializes breakthrough physiologic monitoring platforms for a wide variety of applications.

For more information, please visit www.mindchild.com.

¹ "ACOG Refines Fetal Heart Rate Monitoring Guidelines", 6/22/2009 The American College of Obstetricians and Gynecologists Press Release

² http://www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59_03.pdf

³ Journal of Midwifery. Vol 18, No, 7: 424-428. July 2010

⁴ American Family Physician, 1992 Feb;45(2):579-82

⁵ http://www.aha.org/aha/resource-center/Statistics-and-Studies/fast-facts.html

⁶ Company estimates.